Luigi M E Grimaldi
Overview
Explore the profile of Luigi M E Grimaldi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruggieri S, Ianniello A, Copetti M, Altieri M, Buscarinu M, Centonze D, et al.
Neurotherapeutics
. 2024 Feb;
21(3):e00338.
PMID: 38413275
Despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index -...
2.
Hupperts R, Smolders J, Vieth R, Holmoy T, Marhardt K, Schluep M, et al.
Neurology
. 2019 Oct;
93(20):e1906-e1916.
PMID: 31594857
Objective: In the phase II, randomized, double-blind, placebo-controlled Supplementation of Vigantol Oil versus Placebo Add-on in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Receiving Rebif Treatment (SOLAR) study (NCT01285401), we assessed...
3.
Alongi P, Sardina D, Coppola R, Scalisi S, Puglisi V, Arnone A, et al.
J Neuroimaging
. 2019 Feb;
29(3):383-393.
PMID: 30714241
Background And Purpose: While AD can be definitively confirmed by postmortem histopathologic examination, in vivo imaging may improve the clinician's ability to identify AD at the earliest stage. The aim...
4.
Prosperini L, Annovazzi P, Boffa L, Buscarinu M, Gallo A, Matta M, et al.
J Neurol
. 2018 Sep;
265(12):2851-2860.
PMID: 30259178
In this retrospective, multicenter, real-world study we collected clinical and magnetic resonance imaging (MRI) data of all patients (n = 40) with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab according...
5.
Bagnato S, Grimaldi L, Raimondo G, SantAngelo A, Boccagni C, Virgilio V, et al.
J Neurotrauma
. 2017 Apr;
34(16):2475-2479.
PMID: 28385104
The mechanisms involved in secondary brain injury after the acute phase of severe traumatic brain injury (TBI) are largely unknown. Ongoing axonal degeneration, consequent to the initial trauma, may lead...
6.
Vermersch P, Czlonkowska A, Grimaldi L, Confavreux C, Comi G, Kappos L, et al.
Mult Scler
. 2013 Oct;
20(6):705-16.
PMID: 24126064
Background: In previous studies, teriflunomide significantly reduced the annualised relapse rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods: Patients with...
7.
Grimaldi L, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C
Mult Scler
. 2012 Mar;
18(9):1337-9.
PMID: 22389413
The recommended natalizumab dosage is 300 mg every 4 weeks. We evaluated radiological activity at various times from the last natalizumab infusion by examining 386 magnetic resonance imaging (MRI) scans...
8.
Marino Gammazza A, Bucchieri F, Grimaldi L, Benigno A, de Macario E, Macario A, et al.
Cell Mol Neurobiol
. 2012 Jan;
32(6):943-7.
PMID: 22258649
Heat-shock protein 60 (Hsp60) is ubiquitous and highly conserved being present in eukaryotes and prokaryotes, including pathogens. This chaperonin, although typically a mitochondrial protein, can also be found in other...
9.
Patti F, Amato M, Trojano M, Bastianello S, Tola M, Picconi O, et al.
Qual Life Res
. 2011 Sep;
21(7):1111-21.
PMID: 21953022
Purpose: To report longitudinal changes in and explore the influence of cognition on social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Italian patients (18-50 years) with...
10.
Smolders J, Hupperts R, Barkhof F, Grimaldi L, Holmoy T, Killestein J, et al.
J Neurol Sci
. 2011 May;
311(1-2):44-9.
PMID: 21620416
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has,...